Published in:
Open Access 01-08-2013 | Report
Parenteral ferumoxytol interaction with magnetic resonance imaging: a case report, review of the literature and advisory warning
Published in: Insights into Imaging | Issue 4/2013
Login to get accessAbstract
Background:
Ferumoxytol is a safe and effective parenteral therapy used for the treatment of iron deficiency anaemia that has recently been approved for use in North America and in Europe.
Methods:
Ferumoxytol consists of a superparamagnetic iron oxide (SPIO) core, which causes T1, T2 and T2* shortening effects, and a carbohydrate shell, which results in a prolonged intravascular half life.
Results:
These properties are under-reported and not well recognised. They can interfere with MRI interpretation, potentially masking enhancement and rendering examinations non-diagnostic or simulating pathologic disease states. Both radiologists and non-radiologist physicians must consider the potential interaction of ferumoxytol with MRI when interpreting and prescribing MRI examinations in their patients.
Main Messages
• Ferumoxytol has recently been approved for the treatment of iron deficiency anaemia.
• Ferumoxytol is a small iron oxide particle with prolonged intravascular half life and T1, T2 and T2* shortening effects.
• Administration of ferumoxytol can mask enhancement, rendering MRI studies potentially non-diagnostic.
• Ferumoxytol can mimic diseases such as haemosiderosis, haemochromatosis and superficial siderosis.
• Ferumoxytol interactions with MRI must be recognised by radiologists and non-radiologist physicians.